39 results
424B3
PRE
Prenetics Global Limited
16 Feb 24
Prospectus supplement
6:13am
in the R&D phase, and may not be successful in our efforts to develop any of these or other products into marketable products. Any failure to develop … that are currently in the R&D phase, and may not be successful in our efforts to develop any of these or other products into marketable products. Any failure
F-3
PRE
Prenetics Global Limited
17 Jan 24
Shelf registration (foreign)
6:59am
prospects could be materially and adversely affected.
We have pipeline products that are currently in the R&D phase, and may not be successful in our … be reduced and our revenue could be adversely affected.
We have pipeline products that are currently in the R&D phase, and may not be successful
424B3
PRE
Prenetics Global Limited
2 Nov 23
Prospectus supplement
4:04pm
could be adversely affected.
We have pipeline products that are currently in the R&D phase, and may not be successful in our efforts to develop any … affect our business and future prospects.
We have pipeline products that are currently in the R&D stage. For certain of our pipeline products, before
POS AM
PRE
Prenetics Global Limited
6 Oct 23
Prospectus update (post-effective amendment)
1:52pm
have pipeline products that are currently in the R&D phase, and may not be successful in our efforts to develop any of these or other products … prospects.
We have pipeline products that are currently in the R&D stage. For certain of our pipeline products, before obtaining approvals from regulatory
F-3
PRE
Prenetics Global Limited
29 Sep 23
Shelf registration (foreign)
9:17am
, the demand for our testing services could be reduced and our revenue could be adversely affected.
We have pipeline products that are currently in the R&D … in the R&D stage. For certain of our pipeline products, before obtaining approvals from regulatory authorities for the marketing and sales
424B3
4u3k7gws1tu
21 Jul 23
Prospectus supplement
6:16am
POS AM
el3zbp vw4rpcnyh
6 Jul 23
Prospectus update (post-effective amendment)
9:00am
6-K
EX-99.1
s5putu7jbq8 4p
5 Jun 23
Prenetics Announces First Quarter 2023 Financial Results
7:18am
POS AM
5ezgdeuk3ehbq1g9r
31 May 23
Prospectus update (post-effective amendment)
8:25am
POS AM
ypgfuzta sls4ofj807
1 May 23
Prospectus update (post-effective amendment)
5:19pm
6-K
EX-99.1
j9bw2ylhhwlplk595ch
16 Dec 22
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
8:06am
POS AM
l9eafaq
14 Dec 22
Prospectus update (post-effective amendment)
8:04am
424B3
200tcm me0
1 Jul 22
Prospectus supplement
4:10pm
F-1/A
lgpgzk3r4mzh42 xy
28 Jun 22
Registration statement (foreign) (amended)
4:02pm
F-1/A
pl760m3u32l hpfeg0k5
21 Jun 22
Registration statement (foreign) (amended)
5:07pm
F-1/A
85bimiyms5x3p iglsc
10 Jun 22
Registration statement (foreign) (amended)
4:02pm
F-1
geu6nzk
27 May 22
Registration statement (foreign)
4:26pm
6-K
EX-99.1
mm3ckd 12pts
19 May 22
Current report (foreign)
6:27am
424B3
vm817v8cto3wo 2jd8
11 Apr 22
Prospectus supplement
6:03am